Methods of treatment using lamellarin-class alkaloids

Details Methods of treatment using lamellarin-class alkaloids Methods of treatment using lamellarin-class alkaloids

1995-06-29

1998-12-22

Goldberg, Jerome D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 3144

Patent

active

058520333

ABSTRACT:
The lamellarin compounds disclosed herein have been found to be inhibitors of MDR, i.e., acquired multidrug resistance, which has become a major problem in the treatment of various cancers. The lamellarin compounds disclosed herein have also been found to be cytotoxic to MDR cells. MDR is believed to be associated with certain alterations in tumor cells, including an over-expression of a certain high molecular weight membrane glycoprotein and a decrease in the ability of the tumor cell to accumulate and retain chemotherapeutic agents. The present invention is thus directed to methods of treating MDR-type tumors with an effective anti-MDR amount (either inhibitory or cytotoxic) of one or more lamellarin compounds, which compounds have been found to be effective antitumoral agents against MDR cells.

REFERENCES:
Higgins, C.F. The multidrug resistance P-glycoprotein, Curr. Opin. Cell Biol.5:684-687, 1993.
Nooter, K. et al., Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer 63:663-9, 1991.
Arceci, R.J., Clinical significance of P-glycoprotein in multidrug resistance malignancies, Blood, 81:2215-2222, 1993.
Benchimol, S., et al., P-glycoprotein and tumor progression, J. Natl. Cancer Inst. 86:814-815, 1994.
Tsuruo, T., et al., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-72, 1981.
Deuchars, K., et al., P-glycoprotein and multidrug resistance in cancer therapy. Seminars in Oncology, 16:156-165, 1989.
Gottesman, M.M., et al., Biochemistry of multidrug resistance by the multidrug transporter. Annu. Rev. Biochem., 62:385-427, 1993.
Beck, W.T., et al., Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol, 43:89-93, 1992.
Ozols, R.F., et al., Verapamil and adriamycin in the treatment of drug resistant ovarian cancer patients. J. Clin. Oncol., 5:541-547, 1987.
Andersen, R.J., et al., Metabolites of the marine posobranch mollusc, Lamellaria sp. J. Am. Chem. Soc., 107:5492-5495, 1985.
Linquist, N., et al., New alkaloids of the lamellarin class from the marine ascidian, Didemaun Chartacum (Sluiter, 1909), J. Org. Chem. 53:4570-4574, 1988.
Carroll, A.R., et al., Studies of australians ascidians. I. Six new lamellarin class alkaloids from a colonial ascidian, Didemnum, sp. Aust. J. Chem. 46:489-51, 1993
Mosmann, T. Rapid coorimetric assay for the cellular growth and survival; application to proliferation and cytoxicity assays. Journal of Immunological Methods, 65:55-63, 1983.

Affiliated with

Also associated with

Rating

Methods of treatment using lamellarin-class alkaloids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using lamellarin-class alkaloids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using lamellarin-class alkaloids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2047989